Research Analysts Offer Predictions for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Halozyme Therapeutics in a report released on Sunday, January 12th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $4.96 for the year, down from their previous forecast of $5.11. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics' Q4 2025 earnings at $1.57 EPS, FY2026 earnings at $7.05 EPS, FY2027 earnings at $8.77 EPS and FY2028 earnings at $9.16 EPS.

A number of other equities analysts have also commented on HALO. HC Wainwright raised their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $60.89.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.68 during mid-day trading on Wednesday, reaching $54.51. The company's stock had a trading volume of 1,959,521 shares, compared to its average volume of 1,782,280. The firm's fifty day moving average price is $49.95 and its two-hundred day moving average price is $54.06. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a market capitalization of $6.94 billion, a P/E ratio of 18.05, a PEG ratio of 0.44 and a beta of 1.24.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.40% of the company's stock.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics during the second quarter valued at about $49,000. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $65,000. Finally, Park Place Capital Corp boosted its holdings in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock valued at $78,000 after acquiring an additional 1,209 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.